prof. Valerie Fonteyne

Journal Article
open access

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry

Nicolaas Lumen (UGent) , Elise De Bleser (UGent) , Sarah Buelens (UGent) , Wesley Verla (UGent) , Filip Poelaert (UGent) , Wietse Claeys (UGent) , Valerie Fonteyne (UGent) , Sofie Verbeke (UGent) , Geert Villeirs (UGent) , Kathia De Man (UGent) , et al.

(2021) European Urology Open Science. p.68-76

Add to list

Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer : a systematic review

Kim Van der Eecken (UGent) , Jan Vanwelkenhuyzen (UGent) , Matthew P. Deek, Phuoc T. Tran, Evan Warner, Alexander W. Wyatt, Edmond M. Kwan, Sofie Verbeke (UGent) , Jo Van Dorpe (UGent) , Valerie Fonteyne (UGent) , et al.

(2021) EUROPEAN UROLOGY ONCOLOGY.

Add to list

Supportive roles of the health care team throughout the illness trajectory of bladder cancer patients undergoing radical cystectomy : a qualitative study exploring the patients’ perspectives

Elke Rammant (UGent) , Valerie Fonteyne (UGent) , Vincent Van Goethem (UGent) , Sofie Verhaeghe (UGent) , Anneleen Raes (UGent) , Mieke Van Hemelrijck, Nihal E. Mohamed, Karel Decaestecker (UGent) and Ann Van Hecke (UGent)

(2021) SEMINARS IN ONCOLOGY NURSING. 37(6).

Add to list

Journal Article
A1
open access

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC) : a phase II prospective trial

Flor Verghote (UGent) , Lindsay Poppe (UGent) , Sofie Verbeke (UGent) , Piet Dirix, Maarten Albersen, Gert De Meerleer, Charlien Berghen, Piet Ost (UGent) , Geert Villeirs (UGent) , Pieter De Visschere (UGent) , et al.

(2021) BMC CANCER. 21(1).

Add to list

Journal Article
A2
open access

Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre

Cedric Peters, Julie Vandewiele (UGent) , Yolande Lievens (UGent) , Marc Van Eijkeren (UGent) , Valerie Fonteyne (UGent) , Tom Boterberg (UGent) , Pieter Deseyne (UGent) , Liv Veldeman (UGent) , Wilfried De Neve (UGent) , Christel Monten (UGent) , et al.

(2021) CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY. 27. p.64-69

Add to list

Development of a pre‐ and postoperative physical activity promotion program integrated in the electronic health system of patients with bladder cancer (The POPEYE study) : an intervention mapping approach

Elke Rammant (UGent) , Benedicte Deforche (UGent) , Ann Van Hecke (UGent) , Sofie Verhaeghe (UGent) , Barbara Van Ruymbeke (UGent) , Renée Bultijnck (UGent) , Mieke Van Hemelrijck, Louis Fox, Ronny Pieters, Karel Decaestecker (UGent) , et al.

(2021) EUROPEAN JOURNAL OF CANCER CARE. 30(2).

Add to list

Journal Article
A1
open access

A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE Multi-National Cohort

Michela Carlotta Massi, Francesca Gasperoni, Francesca Ieva, Anna Maria Paganoni, Paolo Zunino, Andrea Manzoni, Nicola Rares Franco, Liv Veldeman (UGent) , Piet Ost (UGent) , Valerie Fonteyne (UGent) , et al.

(2020) FRONTIERS IN ONCOLOGY. 10.

Add to list

PET–CT for staging patients with muscle invasive bladder cancer : is it more than just a fancy tool?

Valerie Fonteyne (UGent) , Kathia De Man (UGent) , Karel Decaestecker (UGent) , Pieter De Visschere (UGent) , P. Dirix, G. De Meerleer, C. Berghen, Piet Ost (UGent) and Geert Villeirs (UGent)

(2020) CLINICAL AND TRANSLATIONAL IMAGING. 9(1). p.83-94

Add to list

Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy

Piet Dirix, Michiel Strijbos, Tom Van den Mooter, Nick Liefhooghe, Siska Van Bruwaene, Pieter Uvin, Christophe Ghysel, Dieter Ost, Peter Schatteman, Samuel Bral, et al.

(2020) FUTURE ONCOLOGY. 16(16). p.1083-1089

Add to list

Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer : an umbrella review

Elke Rammant (UGent) , Lisa Van Wilder (UGent) , Mieke Van Hemelrijck, Nele Pauwels (UGent) , Karel Decaestecker (UGent) , Charles Van Praet (UGent) , Renée Bultijnck (UGent) , Piet Ost (UGent) , Thomas Van Vaerenbergh, Sofie Verhaeghe (UGent) , et al.

(2020) QUALITY OF LIFE RESEARCH. 29. p.2887-2910

Academic Bibliography

prof. Valerie Fonteyne

The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry

Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer : a systematic review

Supportive roles of the health care team throughout the illness trajectory of bladder cancer patients undergoing radical cystectomy : a qualitative study exploring the patients’ perspectives

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC) : a phase II prospective trial

Adoption of single fraction radiotherapy for uncomplicated bone metastases in a tertiary centre

Development of a pre‐ and postoperative physical activity promotion program integrated in the electronic health system of patients with bladder cancer (The POPEYE study) : an intervention mapping approach

A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE Multi-National Cohort

PET–CT for staging patients with muscle invasive bladder cancer : is it more than just a fancy tool?

Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy

Health-related quality of life overview after different curative treatment options in muscle-invasive bladder cancer : an umbrella review

Contents

Support

Contact